5-LOX in Alzheimer’s Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS
- 337 Downloads
The inflammatory process plays a key role in neurodegenerative disorder. The inflammatory molecule, 5-lipooxygenase (5-LOX), protein is involved in the pathologic phenotype of Alzheimer’s disease (AD) which includes Aβ amyloid deposition and tau hyperphosphorylation. This study determined the level of 5-LOX in serum of AD patients, mild cognitive impairment (MCI) patients, and the normal elderly, and the rescue effect by YWCS, a peptide inhibitor of 5-LOX on neurotoxicity by Aβ amyloid25–35 (Aβ25–35) in neuroblastoma cells. The concentration of serum 5-LOX was estimated by surface plasmon resonance and western blot. The neuroprotective effect of 5-LOX peptide inhibitor YWCS in Aβ25–35-induced neurotoxicity was analyzed by MTT assay and western blotting. We found significant upregulated serum 5-LOX in AD patients and also in MCI patients compared to the normal control group. The peptide inhibitor of 5-LOX, YWCS, prevented the neurotoxic effect of Aβ25–35 by reducing the expression of γ-secretase as well as p-Tau181 in SH-SY5Y cells. However, YWCS was nontoxic towards normal HEK cells. The differential expression of serum 5-LOX among the study groups suggests it can be one of potential serum protein marker and a therapeutic regimen for AD and MCI. The negative correlation with neuropsychological parameters, i.e., MoCA and HMSE, increases its importance and makes it useful during the clinical setup which is very needful in developing countries. Peptide YWCS can serve as a new platform as a 5-LOX inhibitor which can prevent neurotoxicity developed in AD.
KeywordsAlzheimer’s disease Aβ25–35 Surface plasmon resonance Neurodegenerative disease Neuroprotective
The authors acknowledge the Research Section, All India Institute of Medical Sciences, for providing the intramural grant and funds for the consumable items and DST, government of India, for the fellowship of Nitish Rai.
Compliance with Ethical Standards
The Ethics Committee of AIIMS approved the study protocol (IESC/T-439/23.12.2014). Informed consent in writing was obtained from the controls, patients, or their attendants (if a patient is incapable of making a signature). The study was carried out as per the guidelines of the Ethics Committee.
- 6.Ganguli M, Ratcliff G, Chandra V, Sharma S, Gilby J, Pandav R, Belle S, Ryan C et al (1995) A Hindi version of the MMSE: the development of a cognitive screening instrument for a largely illiterate rural elderly population in India. International Journal of Geriatric Psychiatry 10:367–377. doi: 10.1002/gps.930100505 CrossRefGoogle Scholar
- 9.O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H et al (2015) STAR-B and BBBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement 11:549–560. doi: 10.1016/j.jalz.2014.08.099 CrossRefPubMedGoogle Scholar
- 11.Ak S, Singh R, Naz F, Chauhan SS, Dinda A, Shukla AA, Gill K, Kapoor V et al (2012) Structure based design and synthesis of peptide inhibitor of human LOX-12: in vitro and in vivo analysis of a novel therapeutic agent for breast cancer. PLoS One 7:e32521. doi: 10.1371/journal.pone.0032521 CrossRefGoogle Scholar
- 24.Habchi J, Arosio P, Perni M, Costa AR, Yagi-Utsumi M, Joshi P, Chia S, Cohen SIA et al (2016) An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Ab42 aggregates linked with Alzheimer’s disease. Sci Adv 2:e1501244. doi: 10.1126/sciadv.1501244 CrossRefPubMedPubMedCentralGoogle Scholar